Solomons Neil
Known title: Chief Medical OfficerCIK: 0001837720
Associated companies
Transaction History
| AUPH | ▲ Buy | Grant | 8,500 | $0 | 3/2/2022 | View on chart |
| AUPH | ▼ Sell | Open Market | 4,846 | $58K | 3/2/2022 | View on chart |
| AUPH | ▲ Buy | Option Exercise | 100,000 | $530K | 11/11/2021 | View on chart |
| AUPH | ▼ Sell | Open Market | 100,000 | $2.9M | 11/11/2021 | View on chart |
| AUPH | ▲ Buy | Option Exercise | 70,000 | $424K | 11/10/2021 | View on chart |
| AUPH | ▲ Buy | Option Exercise | 30,000 | $159K | 11/10/2021 | View on chart |
| AUPH | ▼ Sell | Open Market | 90,000 | $2.8M | 11/10/2021 | View on chart |
| AUPH | ▼ Sell | Open Market | 10,000 | $306K | 11/10/2021 | View on chart |
| AUPH | ▼ Sell | Open Market | 50,000 | $1.5M | 11/9/2021 | View on chart |
| AUPH | ▲ Buy | Option Exercise | 45,000 | $239K | 11/1/2021 | View on chart |
| AUPH | ▼ Sell | Open Market | 45,000 | $1.4M | 11/1/2021 | View on chart |
| AUPH | ▲ Buy | Option Exercise | 150,000 | $480K | 9/13/2021 | View on chart |
| AUPH | ▼ Sell | Open Market | 150,000 | $3.0M | 9/10/2021 | View on chart |
| AUPH | ▼ Sell | Open Market | 5,000 | $79K | 8/25/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
AUPH Appears in Report on Activist Investor Activity
Aurinia Pharmaceuticals was mentioned among stocks drawing attention from activist investors, according to recent financial news coverage. No specific activist involvement details or corporate action plans were detailed in the report. The stock is currently trading between its 52-week range extremes, with analysts maintaining price targets notably above current levels.
AUPH Appears in Report on Activist Investor Activity. Aurinia Pharmaceuticals was mentioned among stocks drawing attention from activist investors, according to recent financial news coverage. No specific activist involvement details or corporate action plans were detailed in the report. The stock is currently trading between its 52-week range extremes, with analysts maintaining price targets notably above current levels.